151. Non-specific effects of leukotriene synthesis inhibitors on HeLa cell physiology.
- Author
-
Sabirsh A, Bristulf J, Karlsson U, Owman C, and Haeggström JZ
- Subjects
- Acetates pharmacology, Acrylates pharmacology, Arachidonate 5-Lipoxygenase biosynthesis, Arachidonic Acids pharmacology, Benzoates pharmacology, Calcium Signaling drug effects, HeLa Cells drug effects, Humans, Indoles pharmacology, Ionomycin pharmacology, Leukocytes enzymology, Leukotriene Antagonists pharmacology, Leukotriene B4 biosynthesis, Organophosphonates pharmacology, Polymerase Chain Reaction, Receptors, Leukotriene B4 genetics, Receptors, Leukotriene B4 physiology, Thapsigargin pharmacology, Thiophenes pharmacology, Transfection, HeLa Cells physiology
- Abstract
We examined the effects of various leukotriene synthesis inhibitors on calcium signalling in HeLa cells, before and after transfection with BLT(1). All of the inhibitors studied were found to reduce increases in intracellular calcium concentration induced by BLT(1), but also by an ionophore or activation of various G-protein coupled receptors, regardless of BLT(1) expression. In order to explore the mechanism of these apparently general effects we examined HeLa cell expression of leukotriene receptors and biosynthetic enzymes and found that the genes for key leukotriene synthesis enzymes and all of the leukotriene receptors were not expressed. Leukotrienes are involved in the pathology of a variety of cancers, and for HeLa cells leukotrienes have been reported to be important for aspects of the carcinogenic phenotype. We find that leukotriene synthesis inhibitors have non-specific effects, so careful controls are necessary to avoid interpreting non-specific effects as evidence for leukotriene involvement.
- Published
- 2005
- Full Text
- View/download PDF